Introduction And Aims: Brief interventions for alcohol problems are informed by elements of behavioural motivation theories and behaviour change models. However, motivations across drinking occasions have yet to be explored. This paper addresses this need and presents initial validity statistics for a new construct, Dose Response Expectancies for Alcohol Metrics (DREAM) that can be used to investigate expectancies across the drinking session and thus inform novel interventions.
Design And Methods: Twenty-seven participants completed a test-retest reliability assessment. Hypothesised systematic relationships between the hypothetical number of drinks consumed across a drinking session and anticipated affective responses were assessed.
Results: The DREAM questionnaire yielded good test-retest statistics for anticipated happiness and nausea in the hours following drinking. Consistent with hypotheses, DREAM yielded a systematic relationship between anticipated alcohol dose and affective response.
Discussion And Conclusions: DREAM offers a novel means to investigate alcohol dose-response expectancies across drinking sessions and to therefore provide a theoretical platform that can be used to inform effective brief interventions for young people.[Adey GE, Moore SC, Chestnutt IG. Dose-response expectancies for alcohol: Validation and implications for brief interventions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1465-3362.2010.00229.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland.
Swiss Med Wkly
January 2025
Cancer Center und Research Center, Cantonal Hospital Graubünden, Chur, Switzerland.
Background And Objective: Because of the lack of effective targeted treatment options, docetaxel has long been the standard second-line therapy for patients with advanced non-small cell lung cancer, including the Kirsten rat sarcoma virus (KRAS) G12C mutation. The CodeBreak 200 trial demonstrated that sotorasib, a new drug targeting the G12C-mutated KRAS protein, modestly improved progression-free survival compared with docetaxel in patients whose cancer had progressed after receiving platinum chemotherapy and programmed cell death protein 1 (PD-1) / programmed death ligand 1 (PD-L1) inhibitors as first-line treatment. Consequently, sotorasib received temporary approval in Switzerland.
View Article and Find Full Text PDFEvaluation of the Safety and Efficacy of Trastuzumab Emtansine (T-DM1) Biosimilar in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: Findings From a Single-Center Retrospective Analysis in India.
Cureus
December 2024
Medical Affairs, Zydus Lifesciences, Ahmedabad, IND.
Background Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a highly aggressive subtype characterized by a high recurrence rate. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate targeting HER2, has shown improved outcomes; however, its effectiveness in cases with brain metastases remains unclear. The T-DM1 biosimilar has emerged as a cost-effective treatment option.
View Article and Find Full Text PDFImpact of Platelet Transfusion at Different Doses in Oncohematology Pediatric Inpatients and Outpatients: A Retrospective Study.
Pediatr Blood Cancer
January 2025
Transfusion Medicine and Cellular Therapy Unit, Policlinico Campus Bio-Medico Foundation, Rome, Italy.
Background: Platelet (PLT) transfusion is an essential strategy to prevent bleeding in children with thrombocytopenia associated to cancer treatment. However, data on optimal pediatric dosing and transfusion thresholds are limited.
Methods: This retrospective study analyzed data from 607 pediatric patients with hematologic malignancies, nonmalignant disorders, and solid tumors who developed hypoproliferative thrombocytopenia during therapy.
Inferring herbicide non-target-site cross-resistance from dose response and mixture treatments.
Pest Manag Sci
January 2025
Syngenta, Jealott's Hill International Research Centre, Bracknell, UK.
Background: Herbicide cross-resistance is of increasing concern because it compromises the effectiveness of both existing and new chemical options. However, a common misconception is that if a weed population shows dose-response shifts to two herbicides, it is cross-resistant to both. The possibility that individual plants may possess different resistance mechanisms is often overlooked.
View Article and Find Full Text PDF[EFFICACY AND SAFETY OF ENFORTUMAB VEDOTIN IN ADVANCED UROTHELIAL CARCINOMA TREATMENT: AN INITIAL EXPERIENCE IN A SINGLE INSTITUTION].
Nihon Hinyokika Gakkai Zasshi
January 2025
Department of Urology, Kurume University School of Medicine.
(Purpose) Enfortumab vedotin has been available as a third-line treatment for advanced urothelial carcinoma in Japan since December 2021. While the treatment is expected to improve the outcome of advanced urothelial carcinoma, concerns regarding adverse events do exist. We report here our initial experience of the use of enfortumab vedotin as a third-line therapy in patients with advanced urothelial carcinoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!